Host Defense Protein Mimetics for Inflammatory Bowel Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases of the gastrointestinal tract, such as ulcerative colitis and Crohn's disease, lack effective curative options, relying on anti-inflammatory steroids with severe side effects and limited efficacy, and there is a need for therapies that can target the underlying inflammatory pathways.
Innovation Solution
The use of host defense protein mimetics, specifically brilacidin (PMX-30063) and delparantag (PMX-60056), which act as phosphodiesterase inhibitors to suppress pro-inflammatory responses by modulating the cyclic AMP/cyclic GMP pathways, reducing inflammation and immune cell activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-inflammatory steroids are used to treat inflammatory diseases of the gastrointestinal tract, then anti-inflammatory efficacy is improved, but severe side effects occur
Solution Approach 1:
The patent uses host defense protein mimetics as intermediary compounds that selectively target inflammatory pathways in the gastrointestinal tract without the systemic immunosuppressive effects of steroids. These mimetics act as mediators between the therapeutic need for anti-inflammatory action and the avoidance of severe side effects by engaging specific immune cell receptors and signaling pathways locally.
Solution Approach 2:
The invention achieves localized anti-inflammatory action in the gastrointestinal tract through orally administered host defense protein mimetics that exert their effects primarily at the site of inflammation. This local quality approach allows therapeutic action where needed while minimizing systemic exposure and associated side effects.
2Reliability
If conventional anti-inflammatory treatments are used, then inflammation is suppressed, but underlying inflammatory pathways are not targeted
Solution Approach 1:
The patent employs host defense protein mimetics that fundamentally change the therapeutic parameter from non-specific anti-inflammatory suppression to targeted modulation of specific inflammatory pathways including NF-κB, MAPK, and cytokine signaling. This parameter change enables selective inhibition of pathogenic inflammatory mechanisms while preserving protective immune functions.
3Reliability
If systemic anti-inflammatory therapies are administered, then broad anti-inflammatory effects are achieved, but systemic toxicity increases
Solution Approach 1:
The invention achieves localized action in the gastrointestinal tract through orally administered host defense protein mimetics that concentrate their therapeutic effect at the site of inflammation. This local quality approach provides broad anti-inflammatory effects where needed while minimizing systemic toxicity through reduced systemic exposure.
Solution Approach 2:
The host defense protein mimetics leverage the body's own immune system mechanisms to achieve anti-inflammatory effects. By mimicking natural host defense proteins, these compounds activate endogenous protective pathways and promote resolution of inflammation through the body's intrinsic regulatory mechanisms, reducing the need for high systemic doses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate significant anti-inflammatory effects by inhibiting TNF-α, MCP-1, MMP-9, and IL-6 production, offering a potential therapeutic approach for inflammatory bowel diseases with reduced systemic toxicity due to localized action in the gastrointestinal tract.
Implementation Method 1
host defense protein mimetics, specifically brilacidin (PMX-30063) and delparantag (PMX-60056), which act as phosphodiesterase inhibitors to suppress pro-inflammatory responses by modulating the cyclic AMP/cyclic GMP pathways
Data Source
AI summary
The present invention provides methods for treating and/or preventing inflammatory diseases of the gastrointestinal tract with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, and the use of compositions comprising the same.